http://www.gosreports.com
Organophosphate and Carbamate Poisoning – Pipeline Review 2020 by Gosreports
Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and some nicotinic symptoms, including muscle fasciculations and weakness. Most patients have bradycardia and, if poisoning is severe, hypotension. CNS toxicity is common, sometimes with seizures and excitability and often with lethargy and coma. Pancreatitis is possible, and organophosphates may cause arrhythmias such as heart block and QTc interval prolongation.
Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Organophosphate and Carbamate Poisoning – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Full Report:
http://www.gosreports.com/global-o-difluoro-benzene-market-research-report-2016/
http://www.gosreports.com/category/latest-reports/page/60/
The Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Organophosphate and Carbamate Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 2 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively for Organophosphate and Carbamate Poisoning.
Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Table of contents:
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Organophosphate and Carbamate Poisoning Overview 6
Therapeutics Development 7
Pipeline Products for Organophosphate and Carbamate Poisoning – Overview 7
Pipeline Products for Organophosphate and Carbamate Poisoning – Comparative Analysis 8
Organophosphate and Carbamate Poisoning – Therapeutics under Development by Companies 9
Organophosphate and Carbamate Poisoning – Therapeutics under Investigation by Universities/Institutes 10
Organophosphate and Carbamate Poisoning – Pipeline Products Glance 11
Early Stage Products 11
Organophosphate and Carbamate Poisoning – Products under Development by Companies 12
Organophosphate and Carbamate Poisoning – Products under Investigation by Universities/Institutes 13
Organophosphate and Carbamate Poisoning – Companies Involved in Therapeutics Development 14
Countervail Corporation 14
Hager Biosciences, LLC 15
Organophosphate and Carbamate Poisoning – Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
AM-132 – Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
galantamine – Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
PlantVax-1502-H-N – Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
RS-194B – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecule for Organophosphate Poisoning – Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning – Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules to Activate Acetylcholinesterase for Organophosphate Poisoning – Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecules to Activate BuChE for Carbamate and Organophosphate Poisoning – Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules to Agonize GABAA for Nerve Gas and Organophosphate Poisoning – Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Organophosphate and Carbamate Poisoning – Discontinued Products 36
Organophosphate and Carbamate Poisoning – Product Development Milestones 37
Featured News & Press Releases 37
Feb 21, 2016: Israeli parent patent for the use of Galantamine and Antimuscarinic Agent For Organophosphorus Poisoning awarded 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39″ “List of Tables
Number of Products under Development for Organophosphate and Carbamate Poisoning, H2 2016 7
Number of Products under Development for Organophosphate and Carbamate Poisoning – Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Products under Investigation by Universities/Institutes, H2 2016 13
Organophosphate and Carbamate Poisoning – Pipeline by Countervail Corporation, H2 2016 14
Organophosphate and Carbamate Poisoning – Pipeline by Hager Biosciences, LLC, H2 2016 15
Assessment by Monotherapy Products, H2 2016 16
Number of Products by Stage and Target, H2 2016 18
Number of Products by Stage and Mechanism of Action H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 24
Organophosphate and Carbamate Poisoning – Discontinued Products, H2 2016 36″ “List of Figures
Number of Products under Development for Organophosphate and Carbamate Poisoning, H2 2016 7
Number of Products under Development for Organophosphate and Carbamate Poisoning – Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy Products, H2 2016 16
Number of Products by Targets, H2 2016 17
Number of Products by Stage and Targets, H2 2016 17
Number of Products by Mechanism of Action, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Routes of Administration, H2 2016 21
Number of Products by Stage and Routes of Administration, H2 2016 21
Number of Products by Molecule Types, H2 2016 23
Number of Products by Stage and Molecule Types, H2 2016 23″ “Countervail Corporation
Hager Biosciences, LLC”
……………………
More Information:
http://www.gosreports.com/global-4-fluoroaniline-market-research-report-2016/
http://www.gosreports.com/global-o-difluoro-benzene-market-research-report-2016/

Contacts Us
Joanna | Executive - International Business and partner Relations
E-mail: [email protected] 
Tel: 001-510-400-8520
Web: www.gosreports.com